

# Carl J Fichtenbaum

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5639801/publications.pdf>

Version: 2024-02-01

122  
papers

5,793  
citations

87401

40  
h-index

87275

74  
g-index

127  
all docs

127  
docs citations

127  
times ranked

5433  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reply to Chu et al. <i>Clinical Infectious Diseases</i> , 2022, 74, 944-945.	2.9	0
2	COVID-19 Vaccination Rates in a Global HIV Cohort. <i>Journal of Infectious Diseases</i> , 2022, 225, 603-607.	1.9	8
3	Is it time to retire efavirenz as a first-line option worldwide?. <i>Aids</i> , 2022, 36, 317-318.	1.0	0
4	Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 349-359.	0.9	4
5	Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2022, 75, 1324-1333.	2.9	8
6	Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 377-381.	0.9	8
7	Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy. <i>Journal of Infectious Diseases</i> , 2022, 226, 1809-1822.	1.9	11
8	Bearing the Burden of Non-AIDS Comorbidities: This Is What Women Aging With Human Immunodeficiency Virus Look Like. <i>Clinical Infectious Diseases</i> , 2021, 72, 1312-1313.	2.9	4
9	Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda. <i>Clinical Infectious Diseases</i> , 2021, 73, e3384-e3390.	2.9	21
10	Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, 2009-2022.	2.9	19
11	Comparison of HIV Screening Strategies in the Emergency Department. <i>JAMA Network Open</i> , 2021, 4, e2117763.	2.8	15
12	Take Your Best Shot: Which SARS-CoV-2 Vaccine Should I Get?. <i>MDM Policy and Practice</i> , 2021, 6, 238146832110312.	0.5	0
13	Monocyte activation in persons living with HIV and tuberculosis coinfection. <i>Aids</i> , 2021, 35, 447-452.	1.0	10
14	Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2021, 223, 352-352.	1.9	0
15	A Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People With HIV on Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab550.	0.4	7
16	Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-Week Results of AIDS Clinical Trials Group A5241 (OPTIONS). <i>Journal of Infectious Diseases</i> , 2020, 221, 1407-1415.	1.9	11
17	Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S8-S19.	1.9	8
18	<i>Mycobacterium bovis</i> Bacille-Calmette-Guérin Infection Aggravates Atherosclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 607957.	2.2	8

#	ARTICLE	IF	CITATIONS
19	Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination. <i>HIV Research and Clinical Practice</i> , 2020, 21, 11-23.	1.1	5
20	Web-Based Data Collection for Older Adults Living With HIV in a Clinical Research Setting: Pilot Observational Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e18588.	2.1	3
21	Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1719-1729.	0.9	10
22	Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. <i>American Heart Journal</i> , 2019, 212, 1-12.	1.2	43
23	Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). <i>American Heart Journal</i> , 2019, 212, 23-35.	1.2	99
24	1255. Comparison in AIDS-Related Mortality Between African Americans and Whites with Human Immunodeficiency Virus During the HAART Era. <i>Open Forum Infectious Diseases</i> , 2019, 6, S451-S451.	0.4	0
25	366. Severe Neurologic Impairment Persists Despite Potent ART in HIV Encephalopathy. <i>Open Forum Infectious Diseases</i> , 2019, 6, S192-S192.	0.4	0
26	Plasma Cystatin C Associates With HIV-Associated Neurocognitive Disorder but Is a Poor Diagnostic Marker in Antiretroviral Therapy-Treated Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e49-e54.	0.9	3
27	Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. <i>Clinical Infectious Diseases</i> , 2019, 68, 1877-1886.	2.9	42
28	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet</i> , The, 2019, 393, 143-155.	6.3	265
29	Serum Bovine Immunoglobulins Improve Inflammation and Gut Barrier Function in Persons with HIV and Enteropathy on Suppressive ART. <i>Pathogens and Immunity</i> , 2019, 4, 124.	1.4	10
30	Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. <i>Vaccine</i> , 2018, 36, 453-460.	1.7	19
31	The Relationship Between Latent Tuberculosis Infection and Acute Myocardial Infarction. <i>Clinical Infectious Diseases</i> , 2018, 66, 886-892.	2.9	46
32	Bone Health in People Living With HIV: The Role of Exercise and Directions for Future Research. <i>Journal of the Association of Nurses in AIDS Care</i> , 2018, 29, 330-337.	0.4	4
33	Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, e112-e114.	0.9	12
34	Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. <i>Aids</i> , 2018, 32, 2517-2524.	1.0	5
35	Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma in Lima, Peru. <i>PLoS ONE</i> , 2018, 13, e0202191.	1.1	12
36	Emerging reverse transcriptase inhibitors for HIV-1 infection. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 149-157.	1.0	36

#	ARTICLE	IF	CITATIONS
37	Evaluation of oral serum-derived bovine immunoglobulins in HIV-infected patients with chronic idiopathic diarrhea. <i>HIV Clinical Trials</i> , 2017, 18, 205-213.	2.0	2
38	Pilot Integration of HIV Screening and Healthcare Settings with Multi - Component Social Network and Partner Testing for HIV Detection. <i>Current HIV Research</i> , 2017, 15, 372-381.	0.2	2
39	The Occurrence of HIV "Blips"™ May Predict the Incidence of Serious Non-AIDS Clinical Events (SNADEs). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
40	Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. <i>Aids</i> , 2016, 30, 1229-1238.	1.0	34
41	Differential CD4+ cell count increase and CD4+. <i>Aids</i> , 2016, 30, 2091-2097.	1.0	9
42	Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department. <i>Clinical Infectious Diseases</i> , 2016, 62, 1066-1071.	2.9	43
43	HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors. <i>Annals of Internal Medicine</i> , 2015, 163, 908-917.	2.0	16
44	Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race"ethnicity determine the degree of regimen complexity. <i>HIV Clinical Trials</i> , 2015, 16, 147-156.	2.0	12
45	Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 1179-1188.	2.9	43
46	Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation. <i>Clinical Infectious Diseases</i> , 2015, 61, 840-849.	2.9	19
47	Comparison of Cardiovascular Disease Risk Markers in HIV-Infected Patients Receiving Abacavir and Tenofovir: The Nucleoside Inflammation, Coagulation and Endothelial Function (Nice) Study. <i>Antiviral Therapy</i> , 2014, 19, 141-147.	0.6	34
48	Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor" Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1. <i>Annals of Internal Medicine</i> , 2014, 161, 461.	2.0	225
49	Entrustment and Mapping of Observable Practice Activities for Resident Assessment. <i>Journal of General Internal Medicine</i> , 2014, 29, 1177-1182.	1.3	104
50	Prevalence of Undiagnosed Acute and Chronic HIV in a Lower-Prevalence Urban Emergency Department. <i>American Journal of Public Health</i> , 2014, 104, 1695-1699.	1.5	10
51	Changes in Fat Mitochondrial DNA and Function in Subjects Randomized to Abacavir-Lamivudine or Tenofovir DF"Emtricitabine With Atazanavir-Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s, Substudy of A5202. <i>Journal of Infectious Diseases</i> , 2013, 207, 604-611.	1.9	42
52	Schistosomiasis, an Unusual Cause of Variceal Bleeding in the United States. <i>Infectious Diseases in Clinical Practice</i> , 2013, 21, 133-135.	0.1	0
53	Randomized Comparison of Universal and Targeted HIV Screening in the Emergency Department. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 315-323.	0.9	64
54	Internal Medicine and Emergency Medicine Physicians Lack Accurate Knowledge of Current CDC HIV Testing Recommendations and Infrequently Offer HIV Testing. <i>Journal of the International Association of Providers of AIDS Care</i> , 2012, 11, 101-108.	1.2	27

#	ARTICLE	IF	CITATIONS
55	Steady-State Pharmacokinetic Interactions of Darunavir/Ritonavir With Lipid-Lowering Agent Rosuvastatin. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 922-931.	1.0	34
56	In Vitro HIV Infection Impairs the Capacity of Myeloid Dendritic Cells to Induce Regulatory T Cells. <i>PLoS ONE</i> , 2012, 7, e42802.	1.1	8
57	Risk, reasons for refusal, and impact of counseling on consent among ED patients declining HIV screening. <i>American Journal of Emergency Medicine</i> , 2011, 29, 367-372.	0.7	16
58	Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection. <i>Current Infectious Disease Reports</i> , 2011, 13, 94-101.	1.3	18
59	Comparison of Missed Opportunities for Earlier HIV Diagnosis in 3 Geographically Proximate Emergency Departments. <i>Annals of Emergency Medicine</i> , 2011, 58, S17-S22.e1.	0.3	27
60	Preliminary Program Evaluation of Emergency Department HIV Prevention Counseling. <i>Annals of Emergency Medicine</i> , 2011, 58, S120-S125.e3.	0.3	4
61	Effect of an Emergency Department HIV Testing Program on the Proportion of Emergency Department Patients Who Have Been Tested. <i>Annals of Emergency Medicine</i> , 2011, 58, S140-S144.	0.3	8
62	Highly Active Antiretroviral Therapy in Patients Infected with Human Immunodeficiency Virus Increases CD40 Ligand Expression and IL-12 Production in Cells Ex Vivo. <i>Viral Immunology</i> , 2011, 24, 281-289.	0.6	4
63	High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection. <i>Aids</i> , 2011, 25, 2053.	1.0	4
64	Frequency of Circulating Regulatory T Cells Increases during Chronic HIV Infection and Is Largely Controlled by Highly Active Antiretroviral Therapy. <i>PLoS ONE</i> , 2011, 6, e28118.	1.1	78
65	Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. <i>Aids</i> , 2010, 24, 885-890.	1.0	46
66	Does Antiretroviral Therapy Increase or Decrease the Risk of Cardiovascular Disease?. <i>Current HIV/AIDS Reports</i> , 2010, 7, 92-98.	1.1	16
67	Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4137-4142.	1.4	91
68	Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. <i>Journal of Clinical Lipidology</i> , 2010, 4, 279-287.	0.6	37
69	Fenofibrate in the treatment of dyslipidemia associated with HIV infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 995-1004.	1.5	10
70	Comparison of emergency department HIV testing data with visit or patient as the unit of analysis. <i>Journal of Medical Screening</i> , 2009, 16, 29-32.	1.1	6
71	Relationship of Self-Reported Prior Testing History to Undiagnosed HIV Positivity and HIV Risk. <i>Current HIV Research</i> , 2009, 7, 580-588.	0.2	9
72	Engagement of the CD4 Receptor Affects the Redistribution of Lck to the Immunological Synapse in Primary T Cells: Implications for T-Cell Activation during Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2009, 83, 1193-1200.	1.5	12

#	ARTICLE	IF	CITATIONS
73	Metabolic abnormalities associated with HIV infection and antiretroviral therapy. <i>Current Infectious Disease Reports</i> , 2009, 11, 84-92.	1.3	17
74	Contributions to early HIV diagnosis among patients linked to care vary by testing venue. <i>BMC Public Health</i> , 2008, 8, 220.	1.2	14
75	Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral Therapy. <i>Journal of the American College of Cardiology</i> , 2008, 52, 569-576.	1.2	278
76	Lipoprotein changes in HIV-infected antiretroviral-naïve individuals after starting antiretroviral therapy: ACTG Study A5152s. <i>Journal of Clinical Lipidology</i> , 2008, 2, 464-471.	0.6	30
77	Short-Term Effect of HAART on Blood Pressure in HIV-Infected Individuals. <i>HIV Clinical Trials</i> , 2008, 9, 52-60.	2.0	17
78	Antiviral Activity of Single-Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV-Infected Adults. <i>Journal of Infectious Diseases</i> , 2008, 198, 1345-1352.	1.9	115
79	A Phase 2, Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 304-309.	0.9	45
80	Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 459-466.	0.9	84
81	Reply to Zhou and Ditangco. <i>Clinical Infectious Diseases</i> , 2007, 44, 148-149.	2.9	0
82	The Prevalence and Significance of Occult Hepatitis B Virus in a Prospective Cohort of HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 309-314.	0.9	63
83	A truvada hypersensitivity reaction simulating abacavir hypersensitivity. <i>Aids</i> , 2007, 21, 2252-2253.	1.0	2
84	Comparison of Direct and Indirect Measurement of LDL-C in HIV-Infected Individuals: ACTG 5087. <i>HIV Clinical Trials</i> , 2007, 8, 45-52.	2.0	23
85	Interpreting and Implementing the 2006 CDC Recommendations for HIV Testing in Health-Care Settings. <i>Public Health Reports</i> , 2007, 122, 579-583.	1.3	26
86	A novel emergency department based prevention intervention program for people living with HIV: evaluation of early experiences. <i>BMC Health Services Research</i> , 2007, 7, 164.	0.9	10
87	Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. <i>Aids</i> , 2006, 20, 725-729.	1.0	41
88	Immune Reconstitution Syndrome in HIV: Validating a Case Definition and Identifying Clinical Predictors in Persons Initiating Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2006, 42, 1639-1646.	2.9	200
89	Safety and Efficacy of Extended-Release Niacin for the Treatment of Dyslipidaemia in Patients with HIV Infection: Aids Clinical Trials Group Study A5148. <i>Antiviral Therapy</i> , 2006, 11, 1081-1090.	0.6	45
90	Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 307-312.	0.9	155

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 143-153.	2.3	87
92	A Randomized Study of the Use of Fluconazole in Continuous versus Episodic Therapy in Patients with Advanced HIV Infection and a History of Oropharyngeal Candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. <i>Clinical Infectious Diseases</i> , 2005, 41, 1473-1480.	2.9	72
93	Pilot Study of Low-Dose Interleukin-2, Pegylated Interferon-1 $\alpha$ 2b, and Ribavirin for the Treatment of Hepatitis C Virus Infection in Patients with HIV Infection. <i>Journal of Infectious Diseases</i> , 2005, 191, 686-693.	1.9	13
94	A Randomized Trial of the Efficacy and Safety of Fenofibrate versus Pravastatin in HIV-Infected Subjects with Lipid Abnormalities: AIDS Clinical Trials Group Study 5087. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 757-767.	0.5	109
95	Safety of Discontinuation of Maintenance Therapy for Disseminated Histoplasmosis after Immunologic Response to Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 38, 1485-1489.	2.9	129
96	Acyclovir-Induced Respiratory Depression in an AIDS Patient With End-Stage Renal Disease on Continuous Ambulatory Peritoneal Dialysis. <i>Infectious Diseases in Clinical Practice</i> , 2004, 12, 304-307.	0.1	1
97	CD40 Ligand Dysregulation in HIV Infection: HIV Glycoprotein 120 Inhibits Signaling Cascades Upstream of CD40 Ligand Transcription. <i>Journal of Immunology</i> , 2004, 172, 2678-2686.	0.4	47
98	Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1358-1366.	0.9	72
99	Coronary Heart Disease Risk, Dyslipidemia, and Management in HIV-Infected Persons. <i>HIV Clinical Trials</i> , 2004, 5, 416-433.	2.0	12
100	Physician specialization and antiretroviral therapy for HIV. <i>Journal of General Internal Medicine</i> , 2003, 18, 233-241.	1.3	62
101	Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. <i>Clinical Infectious Diseases</i> , 2003, 37, 613-627.	2.9	576
102	Leptin Replacement Therapy But Not Dietary Polyunsaturated Fatty Acid Alleviates HIV Protease Inhibitor-Induced Dyslipidemia and Lipodystrophy in Mice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 564-570.	0.9	20
103	Serologic Responses to Epitopes of the Major Surface Glycoprotein of <i>Pneumocystis jirovecii</i> Differ in Human Immunodeficiency Virus-Infected and Uninfected Persons. <i>Journal of Infectious Diseases</i> , 2002, 186, 644-651.	1.9	40
104	The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. <i>Journal of Lipid Research</i> , 2002, 43, 1458-1463.	2.0	37
105	Ischemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2002, 34, 98-102.	2.9	100
106	An Immunocompetent Patient With Primary <i>Scedosporium Apiospermum</i> Vertebral Osteomyelitis. <i>Journal of Spinal Disorders and Techniques</i> , 2002, 15, 425-430.	1.8	26
107	Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. <i>Aids</i> , 2002, 16, 569-577.	1.0	293
108	Interactions Between Antiretroviral Drugs and Drugs Used for the Therapy of the Metabolic Complications Encountered During HIV Infection. <i>Clinical Pharmacokinetics</i> , 2002, 41, 1195-1211.	1.6	155

#	ARTICLE	IF	CITATIONS
109	Specialty training and specialization among physicians who treat HIV/AIDS in the United States. <i>Journal of General Internal Medicine</i> , 2002, 17, 12-22.	1.3	76
110	The Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus Infection. <i>Infectious Diseases in Clinical Practice</i> , 2001, 10, 7-13.	0.1	0
111	HIV Protease Inhibitor Induces Fatty Acid and Sterol Biosynthesis in Liver and Adipose Tissues Due to the Accumulation of Activated Sterol Regulatory Element-binding Proteins in the Nucleus. <i>Journal of Biological Chemistry</i> , 2001, 276, 37514-37519.	1.6	194
112	Elevated Lactate Levels in Hospitalized Persons with HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 195-201.	0.5	16
113	Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. <i>Aids</i> , 2000, 14, 2889-2893.	1.0	46
114	Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. <i>Aids</i> , 2000, 14, 845-852.	1.0	30
115	In Vivo Virulence of <i>Candida albicans</i> Isolates Causing Mucosal Infections in People Infected with the Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2000, 182, 955-959.	1.9	34
116	Refractory Mucosal Candidiasis in Advanced Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2000, 30, 749-756.	2.9	93
117	A Pilot Study of the Management of Uncomplicated Candidemia with a Standardized Protocol of Amphotericin B. <i>Clinical Infectious Diseases</i> , 1999, 29, 1545-1550.	2.9	18
118	Refractory Mucosal Candidiasis in Patients with Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 1998, 26, 556-565.	2.9	71
119	Authors' Reply: <i>Campylobacter</i> spp. Bacteremia in AIDS Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 12, 94.	0.3	0
120	Risk Factors for Dideoxynucleoside-Induced Toxic Neuropathy in Patients with the Human Immunodeficiency Virus Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1995, 10, 169-174.	0.3	46
121	Serious <i>Pseudomonas aeruginosa</i> Infections in Patients Infected with Human Immunodeficiency Virus: A Case-Control Study. <i>Clinical Infectious Diseases</i> , 1994, 19, 417-422.	2.9	70
122	Ehrlichiosis presenting as a life-threatening illness with features of the toxic shock syndrome. <i>American Journal of Medicine</i> , 1993, 95, 351-357.	0.6	113